Q-omics provides the consensus-scored TGFB2 profile across patient tissues and cancer cell-line models. TGFB2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TGFB2 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, TGFB2 RNA expression shows 19,019 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KICH, and THYM as cancer lineages where TGFB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TGFB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TGFB2 survival associations across molecular data types. TGFB2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TGFB2 RNA expression–survival associations across cancer types. High TGFB2 expression shows unfavorable associations in ACC, LGG, MESO, UVM and STAD, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TGFB2 RNA expression.
This table summarizes TGFB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TGFB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TGFB2 shows lower tumor expression in KICH, LUSC, UCEC, LUAD and KIRC and higher tumor expression in LIHC. The KICH box plot shows higher TGFB2 RNA expression in normal versus tumor tissue (log2 FC = −1.668, t-test p < 0.001).
This table shows molecular features associated with TGFB2 in patient tissues and cancer cell lines. In patient samples, TGFB2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TGFB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BONE.
